WANBURYNSEWanbury Limited· PharmaceuticalsHighNegative
Announced Thu, 5 Mar · 12:30 IST

The Exchange had sought clarification from Wanbury Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Consolidated Financial Results not submitted The response of the Company is enclosed.

Regulatory & Legal View source PDF

WANBURY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Wanbury Limited responded to an NSE query dated December 16, 2025, about not submitting consolidated financial results for the quarter ended September 30, 2025 under SEBI LODR Regulation 33. The company explained that its Board, on August 4, 2025, approved the closure and winding up of three foreign subsidiaries — Ningxia Wanbury Fine Chemicals (China), Wanbury Global FZE (UAE) and Wanbury Holdings B.V. (Netherlands) — none of which had commenced any operations. Since the company now has no subsidiaries, only standalone results apply and no consolidated filing is required. The Q1 FY26 results (filed in August) show revenue of Rs. 16,318.40 lakhs and profit after tax of Rs. 1,349.05 lakhs.

Likely market impact

This is a routine compliance clarification, not a penalty or enforcement action. Shareholders should note the company has formally shut down its dormant foreign subsidiaries, which simplifies its structure going forward. No material impact on operations or stock price is expected from this clarification.